Navigation Links
Aratana Therapeutics to Present at Two Upcoming Investor Conferences
Date:11/19/2013

KANSAS CITY, Kan. and BOSTON, Nov. 19, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it will present at the Jefferies 2013 London Healthcare Conference, to be held November 20-21, 2013, in London, UK, and at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentations and will be available to participate in one-on-one meetings with investors who are registered to attend the conferences. 

Event:Jefferies 2013 London Healthcare ConferenceDate: Thursday, November 21, 2013 Time: 10:00 am (Greenwich Mean Time) Location:London, UK 

Event:Piper Jaffray 25th Annual Healthcare ConferenceDate: Wednesday, December 4, 2013 Time: 1:30 pm (Eastern Time)Location:New York, NY

The presentations will be webcast live and remain available for two weeks following the presentation.  To access the webcasts, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical in
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
2. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
3. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
4. Aratana Therapeutics Adds To Drug Development Team
5. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
6. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
7. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
8. Aratana Therapeutics Completes $15 Million Series B Financing
9. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
10. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
11. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer ... EmblemHealth , the New York ... the RedBrick Compass health assessment, combined with the RedBrick ... members. EmblemHealth is among the first health plans in ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... ... being added to the slate of SDS Clinical Trials. Nissan Pilest, Medical Director of Total ... , ... 28, 2009 -- Well known Orange County Dermatologist and Laser Physician, Nissan Pilest , ...
... , , , ... Therapeutics (NYSE Amex: CXM ) and its subsidiary ... completion of their MATRIX Phase 2b clinical study and announced ... Excellarate(TM) product candidate around the end of September. The ...
... , , , , ... (Nasdaq: CYNO ), a leading developer and manufacturer of a broad ... months ended June 30, 2009. , , Second Quarter ... months ended June 30, 2009 were $20.8 million, compared with $39.2 million in ...
Cached Biology Technology:Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division 2Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 2Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 3Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 4Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications 5Cynosure Reports Second Quarter 2009 Financial Results 2Cynosure Reports Second Quarter 2009 Financial Results 3Cynosure Reports Second Quarter 2009 Financial Results 4Cynosure Reports Second Quarter 2009 Financial Results 5Cynosure Reports Second Quarter 2009 Financial Results 6Cynosure Reports Second Quarter 2009 Financial Results 7Cynosure Reports Second Quarter 2009 Financial Results 8Cynosure Reports Second Quarter 2009 Financial Results 9Cynosure Reports Second Quarter 2009 Financial Results 10Cynosure Reports Second Quarter 2009 Financial Results 11Cynosure Reports Second Quarter 2009 Financial Results 12Cynosure Reports Second Quarter 2009 Financial Results 13
(Date:4/17/2014)... Mo. April 17 In the most densely forested ... forests reflect two centuries of human needs, values and ... and clearing forests for agriculture and development, have set ... a U.S. Forest Service study reports. , The report ... conditions and management needs in the Northern United States ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014The development of stem cell ... the ability to characterize stem cell populations based on ... have discovered a new marker that is highly expressed ... umbilical cord blood, which they describe in an article ... from Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia ... makes testing safer, easier, faster and cheaper. , ... is commonly found in soils all over the world ... both humans and animals. The bacteria can survive in ... B. anthracis may occur through skin contact, inhalation ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... A new generation has come of age since the ... and future generations, environmental awareness is an important and ... in environments that offer little chance for direct contact ... sources such as television and educators for information about ...
... have hijacked the human body,s immune response to play tricks ... of this takeover are mixed. The cells essentially welcome the ... while, meaning the human host becomes infected with the TB ... infection remains latent and the infected person never has any ...
... Sept. 29, 2008-The Camille and Henry Dreyfus Foundation announces the ... recognize an individual for exceptional and original research in a ... a major way. The biennial prize of $250,000 is the ... in the U.S. The first prize is scheduled to be ...
Cached Biology News:Children's gardening programs grow environmental stewards 2TB bacterium uses its sugar coat to sweeten its chances of living in lungs 2TB bacterium uses its sugar coat to sweeten its chances of living in lungs 3TB bacterium uses its sugar coat to sweeten its chances of living in lungs 4
... The Fujifilm Life Science LAS-3000 imaging ... with a simplified user interface, providing ... wide range of modularities. The system ... and the perfect standard system for ...
... Life Science LAS-3000mini is a compact ... chemiluminescence applications, and the perfect standard ... 's LAS-3000 provides significantly improved system ... Glowell calibration standards validate that Fujis ...
... 50 assays. The TUNEL-based assay kit ... control cells for convenient detection of DNA ... The assay offers an one-step labeling of ... is a hallmark of apoptosis in mammalian ...
SDS-OutT Precipitation Reagent...
Biology Products: